Thank you
This live web event has ended. Thank you for attending.
This live web event has ended. Thank you for attending.
Heather Landau, MD, is
a hematologist-oncologist and the Director of the Amyloid Program at Memorial
Sloan Kettering (MSK) Cancer Center focused on increasing access to
novel, effective therapies in AL amyloidosis and has investigated drugs at all
stages of development. She has conducted multiple investigator-initiated
clinical trials exploring novel agents and approaches, including consolidation
and maintenance strategies in high-risk patients. She led the development
of MSK’s Outpatient Transplant Service and is studying innovative ways to
optimize high dose therapy and transplant care. Pharmacokinetically dosed
conditioning has the potential to truly personalize high dose therapy and Dr.
Landau has shown that delivering transplant care at home is safe and improves
the quality of life and satisfaction of patients and caregivers.
As an active member of the Amyloid
Research Consortium (ARC), Dr. Landau has worked with the FDA to identify
scientifically rigorous but feasible clinical trials designs and incorporate
clinically meaningful endpoints to accelerate drug approval in this disease.
Translational research efforts focus on using genomic approaches to understand
the biology of pathologic plasma cells in AL amyloidosis, including their
sensitivity and resistance to therapies. Partnering with colleagues in
pathology and clinical laboratory medicine, Dr. Landau is developing more
sensitive methods of detecting and monitoring monoclonal disease using mass
spectrometry.
As a member of the International
Society of Amyloidosis, she has contributed to recently developed clinical
guidelines that highlight best practices for hematopoietic cell
transplantation. She is a member of the International Myeloma Society and International
Kidney Monoclonal Gammopathy Working Group. Dr. Landau’s expertise in the field
of amyloidosis leads to frequent invitations to lecture nationally and
internationally. She also participates regularly in patient-centered
initiatives through the Amyloidosis Research Consortium, Amyloidosis
Foundation, Patient Support Groups and serves as an advisor to Mackenzie’s
Mission.